SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Knight Therapeutics Inc. KHTRF OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • CA • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Knight Therapeutics Inc. (KHTRF) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $5.49. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Financials: revenue is $450M, +15.4%/yr average growth. Net income is $5M (loss), growing at -18.2%/yr. Net profit margin is -1.2% (negative). Gross margin is 33.5% (-13.5 pp trend).

Balance sheet: total debt is $78M against $767M equity (Debt-to-Equity (D/E) ratio 0.1, conservative). Current ratio is 2.39 (strong liquidity). Debt-to-assets is 7.4%. Total assets: $1.0B.

Analyst outlook: 1 / 1 analysts rate KHTRF as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 48/100 (Partial), Past 25/100 (Fail), Health 67/100 (Partial), Moat 35/100 (Fail), Future 100/100 (Pass), Income 10/100 (Fail).

KHTRF SharesGrow Score Overview

48/100

SharesGrow Score

Mixed signals — some strengths

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 48/100

Financials — average growth

PAST 25/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 35/100

Gross margin is + market cap

FUTURE 100/100

Analyst outlook — as buy

INCOME 10/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — KHTRF

No analyst coverage available for this stock.

KHTRF: +15.4%/yr revenue is, -18.2%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

KHTRF: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet KHTRF: Debt-to-Equity (D/E) ratio 0.1 (conservative), Current ratio is 2.39 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

KHTRF: Gross margin is 33.5% (-13.5 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 35/100. ≥ 70 = Pass.

View details →

Analyst outlook: 1 / 1 analysts rate KHTRF as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

KHTRF: Net profit margin is -1.2%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range3.91-5.36

Volume100

Avg Volume (30D)1.54K

Market Cap$538.6M

Beta (1Y)0.04

Share Statistics

EPS (TTM)-0.05

Shares Outstanding$99.57M

IPO Date2014-04-03

Employees745

CEOSamira Sakhia

Financial Highlights & Ratios

Revenue (TTM)$449.72M

Gross Profit$150.62M

EBITDA$54.32M

Net Income$-5.37M

Operating Income$-2.2M

Total Cash$95.21M

Total Debt$77.85M

Net Debt$1.46M

Total Assets$1.05B

Price / Earnings (P/E)-101.9

Price / Sales (P/S)1.2

Analyst Forecast

Rating ConsensusBuy

Analysts Covering1

Buy 100% Hold 0% Sell 0%

Company Info

CountryCA

ExchangeOther OTC

CurrencyUSD

ISINCA4990531069

Price Chart

KHTRF

Knight Therapeutics Inc. ↗ · Other OTC

Healthcare • Drug Manufacturers - Specialty & Generic

3.91 52WK RANGE 5.36

People Also View

Cipher Pharmaceuticals Inc.

Cannara Biotech Inc.

HLS Therapeutics Inc.

RAMM Pharma Corp.

Crescita Therapeutics Inc.

Aion Therapeutic Inc.

Bionoid Pharma Inc.

City View Green Holdings Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message